References
- Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738–1748.
- Edman Kessler L, Wiklander O, Hamberg E, et al. Efficacy and safety of cyclin dependent kinases 4/6 inhibitors in the treatment of metastatic breast cancer: a real-world experience. Acta Oncol. 2020;59(11):1382–1386.
- Iwata H. Clinical development of CDK4/6 inhibitor for breast cancer. Breast Cancer. 2018;25(4):402–406.
- Yap Y-S, Chiu J, Ito Y, et al. Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer. Cancer Sci. 2020;111(9):3313–3326.
- Meynard L, Grellety T. CDK 4/6 inhibitor successful rechallenge after limiting hepatic toxicity. Breast J. 2020;26(2):255–257.
- Raschi E, De Ponti F. Strategies for early prediction and timely recognition of drug-induced liver injury: the case of cyclin-dependent kinase 4/6 inhibitors. Front Pharmacol. 2019;10:1–15.
- Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465–2472.
- Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904–915.
- Bjornsson ES, Bergmann OM, Bjornsson HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144(7):1419–1425.
- Gassert DJ, Garcia H, Tanaka K, et al. Corticosteroid-responsive cryptogenic chronic hepatitis: evidence for seronegative autoimmune hepatitis. Dig Dis Sci. 2007;52(9):2433–2437.
- Yilmaz B, Unlu O, Evcen R, et al. Acute onset seronegative autoimmune hepatitis: are simplified diagnostic criteria sufficient? Eur J Gastroenterol Hepatol. 2016;28(5):607–608.
- Bjornsson ES, Bergmann O, Jonasson JG, et al. Drug-induced autoimmune hepatitis: response to corticosteroids and lack of relapse after cessation of steroids. Clin Gastroenterol Hepatol. 2017;15(10):1635–1636.